Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) received a $6.00 price objective from Piper Jaffray Companies in a research note issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price would suggest a potential upside of 107.61% from the company’s previous close.

Separately, Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Monday, May 22nd.

Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded up 0.70% during midday trading on Monday, hitting $2.89. 584,440 shares of the company were exchanged. Catalyst Pharmaceuticals has a one year low of $0.73 and a one year high of $3.20. The company has a 50-day moving average of $2.80 and a 200 day moving average of $1.91. The company’s market capitalization is $242.14 million.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06). On average, equities research analysts expect that Catalyst Pharmaceuticals will post ($0.26) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Catalyst Pharmaceuticals, Inc. (CPRX) Given a $6.00 Price Target by Piper Jaffray Companies Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/07/catalyst-pharmaceuticals-inc-cprx-given-a-6-00-price-target-by-piper-jaffray-companies-analysts.html.

Large investors have recently bought and sold shares of the company. Oxford Asset Management boosted its stake in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares in the last quarter. Royal Bank of Canada purchased a new stake in Catalyst Pharmaceuticals during the second quarter valued at $117,000. Goldman Sachs Group Inc. boosted its stake in Catalyst Pharmaceuticals by 265.1% in the first quarter. Goldman Sachs Group Inc. now owns 101,855 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 73,958 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Catalyst Pharmaceuticals during the second quarter valued at $149,000. 29.79% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.